At ASH, new data from the MonumenTAL-1 trial that underpins that filing showed that subcutaneous talquetamab achieved an overall response rate (ORR) of 74% at a 0.4 mg/kg dose and 73% at a 0.8 mg ...
Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has a path ... at the American Society of Haematology (ASH) meeting. Updated results from the ...
The central repository of the drug and medication centre helps to navigate to different sections. Medindia's platform provides carefully curated details on generics, brand names, side-effects ...